{"id":39423,"date":"2020-02-05T11:14:47","date_gmt":"2020-02-05T11:14:47","guid":{"rendered":"https:\/\/setterwalls.se\/case\/setterwalls-has-assisted-recipharm-in-connection-with-the-acquisition-of-consort-medical\/"},"modified":"2025-01-13T09:28:22","modified_gmt":"2025-01-13T08:28:22","slug":"setterwalls-has-assisted-recipharm-in-connection-with-the-acquisition-of-consort-medical","status":"publish","type":"assignments","link":"https:\/\/setterwalls.se\/en\/case\/setterwalls-has-assisted-recipharm-in-connection-with-the-acquisition-of-consort-medical\/","title":{"rendered":"Setterwalls has assisted Recipharm in connection with the acquisition of Consort Medical"},"content":{"rendered":"<p><strong>Setterwalls has assisted Recipharm AB (publ) in connection with an offer to acquire all shares in Consort Medical plc.<\/strong><\/p>\n<p>The enlarged Recipharm Group is set to become a top five global CDMO (Contract Development and Manufacturing Organisation), able to offer integrated device development and supply combined with commercial scale finished dose manufacturing. The shareholders in Consort Medical receives a consideration of GBP 10.10 per share, in cash, which represents an equity value of GBP 505 million (SEK 6,284 million) on a fully diluted basis. The offer is fully financed through bank facilities including a bridge facility of SEK 2,000 million. For further information about the acquisition and Recipharm, please refer to the company\u2019s website: <a href=\"https:\/\/www.recipharm.com\/\">www.recipharm.com.<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p><strong>Setterwalls has assisted Recipharm AB (publ) in connection with an offer to acquire all shares in Consort Medical plc.<\/strong><\/p>\n<p>The enlarged Recipharm Group is set to become a top five global CDMO (Contract Development and Manufacturing Organisation), able to offer integrated device development and supply combined with commercial scale finished dose manufacturing. The shareholders in Consort Medical receives a consideration of GBP 10.10 per share, in cash, which represents an equity value of GBP 505 million (SEK 6,284 million) on a fully diluted basis. The offer is fully financed through bank facilities including a bridge facility of SEK 2,000 million. For further information about the acquisition and Recipharm, please refer to the company\u2019s website: <a href=\"https:\/\/www.recipharm.com\/\">www.recipharm.com.<\/a><\/p>\n","protected":false},"author":1,"featured_media":33999,"template":"","meta":{"_acf_changed":true,"_seopress_robots_primary_cat":"","_seopress_titles_title":"","_seopress_titles_desc":"","_seopress_robots_index":""},"class_list":["post-39423","assignments","type-assignments","status-publish","has-post-thumbnail","hentry"],"acf":[],"_links":{"self":[{"href":"https:\/\/setterwalls.se\/en\/wp-json\/wp\/v2\/assignments\/39423","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/setterwalls.se\/en\/wp-json\/wp\/v2\/assignments"}],"about":[{"href":"https:\/\/setterwalls.se\/en\/wp-json\/wp\/v2\/types\/assignments"}],"author":[{"embeddable":true,"href":"https:\/\/setterwalls.se\/en\/wp-json\/wp\/v2\/users\/1"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/setterwalls.se\/en\/wp-json\/wp\/v2\/media\/33999"}],"wp:attachment":[{"href":"https:\/\/setterwalls.se\/en\/wp-json\/wp\/v2\/media?parent=39423"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}